

PRO DEX Inc. (PDEX)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000788920

PRO DEX Inc. PDEX; healthcare						
Grade	A	 strongest fifth of 371 graded peers percentile 11.4; sampling error 2.5 points; lower is stronger				
Rank	43 of 371					
Profitability	C	 percentile 47.7				
Solvency	B	 percentile 26.0				
Growth and financing	B	 percentile 27.3				
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025					
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025					
Size band	\$12.5M to \$120M assets total assets \$74.5M					
Standard universe	inside revenue above \$1M and assets above \$10M					
Warnings	none active					
Inputs computable	12 of 14					
Graded from	filings received through Sep 3, 2026 36 days before the rescan; latest periodic filing 10-K received Sep 3, 2026					
Last close	\$61.87 2026-10-08; market equity \$198.2M					
Price used in grade	None					

A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers


Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: A/B from Sep 21, 2023, A from Feb 21, 2025, A/B from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Sep 3, 2026

"Pro-Dex," "we," "our," "us") specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial ("CMF") markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality and regulatory consulting services to our customers. We also manufacture and sell rotary air motors to a wide range of industries; however, these motors comprise a de minimis

portion of our business.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.7						
Gross profitability		32.7%	32.2%	45.0	372	2026-06-30
Return on invested capital		18.1%	9.3%	23.3	74	2026-06-30
Accruals ratio		9.5%	(6.6%)	91.0	811	2026-06-30
Gross margin stability, five years		1.8 pts	2.8 pts	31.4	243	2026-06-30
Solvency, sleeve percentile 26.0						
Twelve-month failure probability		0.03%	0.07%	15.0	248	2026-06-30
Altman Z double-prime		8.66	(0.31)	10.7	756	2026-06-30
Net debt to EBITDA		0.65x	1.82x	33.8	75	2026-06-30
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30
Current ratio		4.10x	2.96x	44.5	839	2026-06-30
Growth and financing, sleeve percentile 27.3						
Revenue growth, three-year compound		18.9%	10.0%	32.9	415	2026-06-30
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 12
Reinvestment rate		67.9%	37.1%	40.8	104	2026-06-30
Asset growth, three years		12.9%	2.1%	28.0	704	2026-06-30
Net share issuance, one year		(1.8%)	2.5%	7.4	634	2026-09-02

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	TG Therapeutics, Inc. (TGTX)	10.5	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	PRO DEX Inc. (PDEX) <	11.4	A	
44	Sanara MedTech Inc. (SMTI)	11.6	A	
45	Orthopediatrics Corp. (KIDS)	11.9	A	

46	Idexx Laboratories Inc. (IDXX)	12.2	A
47	Procept BioRobotics Corp. (PRCT)	12.4	A fortress balance sheet
48	Natera, Inc. (NTRA)	12.7	A fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	83.5%	8.0%	85
Distance from 52-week high	(15.3%)	(31.4%)	72
EBIT to enterprise value	6.2%	(1.5%)	82
Free cash flow yield	3.4%	(1.0%)	71
Book value to price	0.24	0.28	46
Sales to price	0.39	0.31	57
Composite equity issuance, five years	(12.9%)	20.3%	13
Relative strength against the sector, log excess return	0.39	(0.14)	85

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$8.2M
Operating cash flow, four quarters	\$7.2M
Months of runway	not finite
Days since last periodic filing	36 (10-K received Sep 3, 2026)
Median daily dollar volume, 63 sessions	\$4.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$24.3M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
2	assets	us-gaap:Assets	\$74.5M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
3	operating income	us-gaap:OperatingIncomeLoss	\$13.0M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$18.0M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$4.4M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
6	total debt	us-gaap:LongTermDebt	\$17.5M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
7	book equity	us-gaap:StockholdersEquity	\$47.6M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$8.2M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
9	total debt	us-gaap:LongTermDebt	\$15.4M	2025-06-30	2025-09-04	10-K	0001079973-25-001426
10	book equity	us-gaap:StockholdersEquity	\$36.6M	2025-06-30	2026-09-03	10-K	0001079973-26-001215
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$419,000	2025-06-30	2026-09-03	10-K	0001079973-26-001215
12	net income	us-gaap:NetIncomeLoss	\$13.7M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.2M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
14	assets	us-gaap:Assets	\$61.2M	2025-06-30	2026-09-03	10-K	0001079973-26-001215
15	revenue	us-gaap:Revenues	\$77.5M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
16	gross profit	us-gaap:GrossProfit	\$19.5M	2025-06-30	2026-09-03	10-K	0001079973-26-001215
17	revenue	us-gaap:Revenues	\$66.6M	2025-06-30	2026-09-03	10-K	0001079973-26-001215

18	gross profit	us-gaap:GrossProfit	\$14.6M	2024-06-30	2025-09-04	10-K	0001079973-25-001426
19	revenue	us-gaap:Revenues	\$53.8M	2024-06-30	2025-09-04	10-K	0001079973-25-001426
20	gross profit	us-gaap:GrossProfit	\$12.7M	2023-06-30	2024-09-05	10-K	0001553350-24-000079
21	revenue	us-gaap:Revenues	\$46.1M	2023-06-30	2024-09-05	10-K	0001553350-24-000079
22	gross profit	us-gaap:GrossProfit	\$13.1M	2022-06-30	2023-10-13	10-K	0001079973-23-001429
23	revenue	us-gaap:Revenues	\$42.0M	2022-06-30	2023-10-13	10-K	0001079973-23-001429
24	current assets	us-gaap:AssetsCurrent	\$53.2M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
25	current liabilities	us-gaap:LiabilitiesCurrent	\$13.0M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$47.6M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
27	liabilities	us-gaap:Liabilities	\$26.9M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.4M	2026-06-30	2026-09-03	10-K	0001079973-26-001215
29	operating income	us-gaap:OperatingIncomeLoss	\$5.8M	2023-06-30	2024-09-05	10-K	0001553350-24-000079
30	interest expense	us-gaap:InterestExpense	\$533,000	2023-06-30	2023-10-13	10-K	0001079973-23-001429
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$483,000	2026-06-30	2026-09-03	10-K	0001079973-26-001215
32	current assets	us-gaap:AssetsCurrent	\$47.3M	2025-06-30	2026-09-03	10-K	0001079973-26-001215
33	current liabilities	us-gaap:LiabilitiesCurrent	\$14.6M	2025-06-30	2026-09-03	10-K	0001079973-26-001215
34	assets	us-gaap:Assets	\$52.5M	2024-06-30	2025-09-04	10-K	0001079973-25-001426
35	assets	us-gaap:Assets	\$51.8M	2023-06-30	2024-09-05	10-K	0001553350-24-000079
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,203,334	2026-09-02	2026-09-03	10-K	0001079973-26-001215
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,261,979	2025-09-03	2025-09-04	10-K	0001079973-25-001426